Insights |  

By Topic

Clear All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Small Caps & Emerging Stocks

Duratec (ASX:DUR) Wins $281m AUKUS Contract: Is This Small Cap a Buy Now?

Duratec Limited (ASX:DUR) surged after its 50:50 Duratec Ertech Joint Venture secured a A$281 million Department of Defence contract for major upgrades at HMAS Stirling. The win strengthens Duratec’s position within Australia’s AUKUS infrastructure program, but the stock’s strong rally and higher valuation mean investors may need to weigh momentum against entry risk.

Small Caps & Emerging Stocks
Small Caps
Consumer Discretionary

Guzman y Gomez (ASX:GYG) Surges 18% on Q3 Sales Beat: Is the Turnaround Finally Real?

The result showed stronger sales growth, improving margins, and positive signs from its delivery partnership, which helped drive the sharp share price move. Even so, investors still need to watch whether this momentum can continue and if the US expansion starts contributing in a meaningful way

Consumer Discretionary
Growth
Consumer Discretionary

Australia's Tourism Boom: ASX Consumer Discretionary Stocks to Watch in 2026

This article explores how Australia’s tourism recovery is creating fresh opportunities in ASX consumer discretionary stocks in 2026. It explains the structural drivers behind the rebound and highlights the listed companies most exposed to rising travel demand.

Consumer Discretionary
ASX 200
Growth Stocks
Small Caps & Emerging Stocks

Small-Cap Growth Stocks in Focus: Are ASX Micro-Caps Setting Up for a Re-Rating in 2026?

This article looks at whether the recent pullback in ASX micro-caps and small-cap growth stocks is a warning sign or a fresh opportunity for investors in 2026. It explains the earnings gap, valuation disconnect, sector tailwinds, and company-specific risks shaping the small-cap outlook.

Growth Stocks
Small Caps
Financials including Banking

Pepper Money (ASX:PPM) Falls Sharply on Challenger's Reduced Bid- But the Business Tells a Different Story

Challenger cut its offer for Pepper Money from A$2.60 to A$2.25 per share, creating fresh uncertainty around whether a deal will happen at all. That pushed PPM shares lower, even as its latest FY2025 numbers remained strong.

Financials including Banking
Interest Rates
ASX 200 Today

CSL's Leadership Shock: What CEO Exits Mean for ASX Healthcare

CSL Limited (ASX: CSL), Australia's largest healthcare company, dropped a bombshell on investors this week. On 10 February, the company announced that CEO Dr Paul McKenzie was leaving, effective immediately. Shares crashed around 5% in the closing auction, finishing at A$171.39. The very next morning, weak half-year earnings sent shares plunging again, falling as low as A$151.30 before recovering to around A$163.44, an eight-year low.

ASX 200 Today
CSL

Our friendly team is here to help.

If you have any questions or feedback about our service, please feel free to contact us.

Contact Us
ASR
HomeCompaniesServicesInsightsEducationSMSF
Insights
By Topic
By Sector
Market Updates
Top Stocks
Education
Types of Shares
Learning Centre
How to Invest
Learn to Invest
Documents
Financial Services GuidePrivacy PolicyComplaints PolicyTermsDisclaimer
Australian Stock Report is part of the AAIG family of Companies
*prices on atleast a 20min delay
Data provided by  
Factset logo
© Australian Stock Report Pty Ltd. All rights reserved